Genetically engineered human herpes simplex virus in the treatment of brain tumours.
Herpes
; 8(1): 17-22, 2001 Mar.
Article
em En
| MEDLINE
| ID: mdl-11867012
ABSTRACT
Central nervous system malignancies--particularly glioblastoma multiforme--pose significant problems for the development of novel therapeutics. In the absence of advances with standard surgical and chemotherapeutic approaches, the utilization of genetically engineered viruses--both as direct oncolytic agents (virus therapy) and for the delivery of foreign proteins (gene therapy)--represents a significant advance in the experimental approach to the management of patients with incurable tumours. Among other viruses, herpes simplex virus (HSV) offers an opportunity to influence the replication of tumour cells directly within the central nervous system. The propensity for HSV to replicate in tumour cells, and its large coding capacity, provide an experimental model for the development of novel therapeutics. The status of these experimental approaches and Phase I studies are summarized.
Buscar no Google
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Terapia Genética
/
Neoplasias do Sistema Nervoso Central
/
Simplexvirus
/
Glioma
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Herpes
Assunto da revista:
VIROLOGIA
Ano de publicação:
2001
Tipo de documento:
Article
País de afiliação:
Estados Unidos